Acute care costs of patients admitted for management of chronic obstructive pulmonary disease exacerbations: contribution of disease severity, infection and chronic heart failure
- PMID: 20180870
- DOI: 10.1111/j.1445-5994.2010.02195.x
Acute care costs of patients admitted for management of chronic obstructive pulmonary disease exacerbations: contribution of disease severity, infection and chronic heart failure
Abstract
Background: In 2003, chronic obstructive pulmonary disease (COPD) accounted for 46% of the burden of chronic respiratory disease in the Australian community. In the 65-74-year-old age group, COPD was the sixth leading cause of disability for men and the seventh for women.
Aims: To measure the influence of disease severity, COPD phenotype and comorbidities on acute health service utilization and direct acute care costs in patients admitted with COPD.
Methods: Prospective cohort study of 80 patients admitted to the Royal Melbourne Hospital in 2001-2002 for an exacerbation of COPD. Patients were followed for 12 months and data were collected on acute care utilization. Direct hospital costs were derived using Transition II, an activity-based costing system. Individual patient costs were then modelled to ascertain which patient factors influenced total direct hospital costs.
Results: Direct costs were calculated for 225 episodes of care, the median cost per admission was AU$3124 (interquartile range $1393 to $5045). The median direct cost of acute care management per patient per year was AU$7273 (interquartile range $3957 to $14 448). In a multivariate analysis using linear regression modelling, factors predictive of higher annual costs were increasing age (P= 0.041), use of domiciliary oxygen (P= 0.008) and the presence of chronic heart failure (P= 0.006).
Conclusion: This model has identified a number of patient factors that predict higher acute care costs and awareness of these can be used for service planning to meet the needs of patients admitted with COPD.
Similar articles
-
Burden of chronic obstructive pulmonary disease in Medicare beneficiaries residing in long-term care facilities.Am J Geriatr Pharmacother. 2009 Oct;7(5):262-70. doi: 10.1016/j.amjopharm.2009.11.003. Am J Geriatr Pharmacother. 2009. PMID: 19948302
-
An integrated care facilitation model improves quality of life and reduces use of hospital resources by patients with chronic obstructive pulmonary disease and chronic heart failure.Aust J Prim Health. 2010;16(4):326-33. doi: 10.1071/PY10007. Aust J Prim Health. 2010. PMID: 21138701 Clinical Trial.
-
[Costs of exacerbations of chronic obstructive pulmonary disease in primary and secondary care in 2007--results of multicenter Polish study].Pol Merkur Lekarski. 2009 Mar;26(153):208-14. Pol Merkur Lekarski. 2009. PMID: 19388534 Polish.
-
Epidemiology and global impact of chronic obstructive pulmonary disease.Semin Respir Crit Care Med. 2005 Apr;26(2):204-10. doi: 10.1055/s-2005-869539. Semin Respir Crit Care Med. 2005. PMID: 16088437 Review.
-
The impact of severe exacerbations on quality of life and the clinical course of chronic obstructive pulmonary disease.Am J Med. 2006 Oct;119(10 Suppl 1):38-45. doi: 10.1016/j.amjmed.2006.08.006. Am J Med. 2006. PMID: 16996898 Review.
Cited by
-
Combination inhaled steroid and long-acting beta₂-agonist in addition to tiotropium versus tiotropium or combination alone for chronic obstructive pulmonary disease.Cochrane Database Syst Rev. 2016 Jun 6;2016(6):CD008532. doi: 10.1002/14651858.CD008532.pub3. Cochrane Database Syst Rev. 2016. PMID: 27271056 Free PMC article.
-
The effect of adding inhaled corticosteroids to tiotropium and long-acting beta(2)-agonists for chronic obstructive pulmonary disease.Cochrane Database Syst Rev. 2011 Sep 7;2011(9):CD009039. doi: 10.1002/14651858.CD009039.pub2. Cochrane Database Syst Rev. 2011. PMID: 21901729 Free PMC article.
-
Single-inhaler triple therapy utilizing the once-daily combination of fluticasone furoate, umeclidinium and vilanterol in the management of COPD: the current evidence base and future prospects.Ther Adv Respir Dis. 2018 Jan-Dec;12:1753466618760779. doi: 10.1177/1753466618760779. Ther Adv Respir Dis. 2018. PMID: 29537340 Free PMC article. Review.
-
Long-acting beta2-agonists for chronic obstructive pulmonary disease.Cochrane Database Syst Rev. 2013 Oct 15;2013(10):CD010177. doi: 10.1002/14651858.CD010177.pub2. Cochrane Database Syst Rev. 2013. PMID: 24127118 Free PMC article.
-
Tiotropium versus placebo for chronic obstructive pulmonary disease.Cochrane Database Syst Rev. 2014 Jul 21;2014(7):CD009285. doi: 10.1002/14651858.CD009285.pub3. Cochrane Database Syst Rev. 2014. PMID: 25046211 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical